Myrexis cancer news
Myrexis said it would restructure and reduce headcount by 15 (19%) to 62 after discontinuing development of Azixa verubulin earlier this year. The small molecule microtubule destabilizing apoptosis-inducer was in Phase IIb testing for glioblastoma multiforme (GBM). Myrexis said the cuts will generate annual savings of about $1.8 million. Myrexis has exclusive rights to Azixa, which has Orphan Drug designation in the U.S. for the indication, from EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT, Tarrytown, N.Y.). The company said it would focus on its remaining cancer programs, the most advanced of which is MPC-3100. The fully-synthetic, non-geldanamycin small molecule inhibitor of heat shock protein 90 (Hsp90) completed a Phase I trial for refractory or relapsed cancer. ...